Unsure which funding opportunity is right for you? Use our investor matching tool to help you on to your next stepFind investor
Takes less than ~2 min to complete
A European venture capital firm, dedicated to investments in the field of life science. Their investment strategy is focused on diseases with high unmet medical needs and breakthrough therapies. Through their investments, HealthCap wants to change medical practice and the lives of patients.
IMPACT Partners is uniquely positioned to support social impact entrepreneurs through our 4 offices in Europe. IMPACT Partners was founded by private investors in 2007 following the social riots in France in 2005. We made a double promise of achieving financial performance and social impact, which are equally important to us. We believe real impact can only be done by scaling viable solutions. We invest in companies that encourage a significant social impact, particularly in deprived areas (social inclusion, circular economy, local development, etc.) to improve social/disability employment and reduce labour market disparities. IMPACT Partners also invest in companies with broader social impact products and services (e.g. within health, education and welfare). Our current fund invests in series A-B.
In short CCIT comprise clinical and experimental expertise in tumor immunology. The Centre has approx. 25 employees; scientists, clinicians, PhD students, as well as technicians. The Centre has extensive experience in initiating clinical trials in cancer, and more than 100 cancer patients have been vaccinated with dendritic cell based therapeutic vaccinations and new facilities for GCP production of cellular products for clinical use was recently opened, enabling trials using adoptive cell transfer of tumor specific T cells. Currently 5 trials are active (www.clinicaltrial.gov), including patients with both solid and hematological malignancies. Concerning experimental cancer research the laboratory is equipped with state of the art instruments for flow cytometry (eg. 2 FACSAria and one LSR-II instrument), cell culture, PCR, in house construction of recombinant proteins (HLA molecules), DNA and RNA transfections, serum analyses, ect. Main experimental contributions have been made in characterization of tumor antigens recognized by CD8 T cells, studies of T cell biology, cancer genetics, dendritic cell biology, regulatory T cells, and biological monitoring of therapeutic vaccination trials, ect.
The Nordic Eye is a Danish Venture capital firm based in Copenhagen and Los Angeles, California. They invest in carefully selected and mainly Nordic early-growth companies in tech and lifestyle business areas. They look for companies that can scale globally and where they can add value while helping to provide great exit opportunities within approximately five years.
MBA in International business from European school of economics. Entrepreneur & Investor posses strong background in startup, marketing, sales and business strategies. Co-founder Fairlo- financial services made truly fair. 8 years within MTG (Kinnevik) where I worked with sales and marketing both operational and strategical.
Ole Jensen is a professional and committed leader with a carrier of more than 30 years within international oriented B-t-B sales and services of technical solutions in a variety of industries as IT; Test & Measurement instruments and systems; RF and Electromechanical components for Telecommunications; Robotics, PLC, Motion, Drives, Sensing, Safety and Component within Machine Automation. Ole has a background with establishing regional subsidiaries including production, starting up agents and distribution channels. Strategically tasks making / implementing strategic plans, managing larger organization with constantly development on a daily basis.
I have solid profit improvement track record from industrial line manager and senior executive roles, combined with 10 years Consulting experience from leading Management Consulting Firms. As consultant I have sold, lead and delivered Operational Excellence, Lean, Supply Chain Management and Procurement transformation projects and analyses in leading corporations.
Great things happen through good partnerships. My focus is to establish partnerships where everyone involved feels motivated, challenged and with the desire to be continuously evolving. This is in every aspect of my life – including as a business leader, board member, investor, mentor, coach and ski instructor.
BRING US YOUR MOONSHOT STARTUPS! ESA BIC Denmark is the 21st member of ESA’s pan-European network of Business Incubation Centres. The incubator is lead by The Technical University of Denmark (DTU) in collaboration with the Danish Ministry for Higher Education and Science, University of Aalborg, University of Aarhus, The Danish Industry Foundation and other partners from academia, science parks, industry and Danish government agencies. Each start-up that is accepted into ESA BIC Denmark and associated with a regional ESA BIC incubation hub will be provided with a free-of-charge package of business coaching, technical support and cash incentives during an incubation period of up to two years. The main elements of this package are: - €50.000 in financial incentives - Business development support - Technical support - Access to funding - Office space at favourable rates
Ivan Bjerg-Larsen has actively operated and invested in many different types of companies over the years. Our future focus is through partnerships to invest in companies where we can contribute to business development and support the day-to-day management of our core competencies in strategy development, controlling and financing.
We help entrepreneurs and venture capital fund managers turn promising ideas into market-defining and market-leading businesses. We are committed to spreading the Foundry Group ethos through our investment activity as well as in the other ways we engage with the entrepreneurial ecosystem.